logo
Twitter
Discord
Email
logo
Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

NYSE•CRL
CEO: Mr. James C. Foster J.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2000-06-23
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Contact Information
251 Ballardvale Street, Wilmington, MA, 01887, United States
781-222-6000
www.criver.com
Market Cap
$9.50B
P/E (TTM)
-137.0
35.6
Dividend Yield
--
52W High
$199.66
52W Low
$91.86
52W Range
94%
Rank36Top 23.7%
4.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$1.00B-0.49%
4-Quarter Trend

EPS

$1.11-17.16%
4-Quarter Trend

FCF

$178.25M-16.34%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

RMS Segment Revenue Growth RMS revenue grew 2.4% (9M) to $639.8M; operating income rose 13.2% to $113.9M, driven by Noveprim sales.
Strong Operating Cash Flow Operating cash flow increased 2.6% (9M) to $590.1M, primarily driven by lower variable compensation payments.
Restructuring Cost Savings Restructuring actions expected to yield $225M annualized cost savings, with $175M impacting fiscal year 2025.
New Share Repurchase Authorization Board approved new $1.0B stock repurchase authorization, replacing the prior plan which had $549.3M remaining.

Risk Factors

Operating Income Significantly Declined Nine-month operating income fell 21.9% to $308.6M due to accelerated amortization and restructuring charges.
Manufacturing Profitability Collapse Manufacturing operating income dropped 61.0% (9M) to $43.4M, primarily due to loss of key CDMO customers.
Ongoing SEC Investigation Risk SEC inquiry regarding non-human primate sourcing continues; outcome and potential liabilities remain unpredictable.
Higher Effective Tax Rate Effective tax rate increased 820 bps (9M) to 31.1% due to net U.S. taxation of foreign operations.

Outlook

Strategic Portfolio Focus Divesting non-core assets, representing 7% of 2025 revenue, to strengthen leading scientific portfolio within core markets.
Targeted Annual Cost Reductions Implementing initiatives aiming for $70M incremental net cost savings annually, fully realized by 2026.
NAM Technology Advancement Supporting FDA pilot programs for New Approach Methodologies (NAMs) to streamline drug development process.
Disciplined Capital Deployment Maintaining disciplined approach evaluating optimal balance between strategic acquisitions, stock repurchases, and debt repayment.

Peer Comparison

Revenue (TTM)

Henry Schein, Inc.HSIC
$12.94B
+3.5%
Charles River Laboratories International, Inc.CRL
$4.02B
-0.9%
AptarGroup, Inc.ATR
$3.66B
+2.5%

Gross Margin (Latest Quarter)

HealthEquity, Inc.HQY
70.8%
+5.2pp
Guardant Health, Inc.GH
64.7%
+3.6pp
Masimo CorporationMASI
62.1%
+9.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
GH$12.67B-31.9151.9%101.8%
RVTY$11.92B49.63.2%27.8%
CRL$9.50B-137.0-2.0%36.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.1%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 18, 2026
|
EPS:$2.32
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 27, 2025|Filed: Nov 5, 2025|
    Revenue: $1.00B-0.5%
    |
    EPS: $1.11-17.2%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 28, 2025|Filed: Aug 6, 2025|
    Revenue: $1.03B+0.6%
    |
    EPS: $1.06-39.4%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 29, 2025|Filed: May 7, 2025|
    Revenue: $984.17M-2.7%
    |
    EPS: $0.50-61.8%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 28, 2024|Filed: Feb 19, 2025|
    Revenue: $4.05B-1.9%
    |
    EPS: $0.20-97.8%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 28, 2024|Filed: Nov 6, 2024|
    Revenue: $1.01B-1.6%
    |
    EPS: $1.34-21.2%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 29, 2024|Filed: Aug 7, 2024|
    Revenue: $1.03B-3.2%
    |
    EPS: $1.75-7.4%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 30, 2024|Filed: May 9, 2024|
    Revenue: $1.01B-1.7%
    |
    EPS: $1.31-34.8%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 30, 2023|Filed: Feb 14, 2024|
    Revenue: $4.13B+3.9%
    |
    EPS: $9.27-3.1%
    Beat